Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Amorepacific is Koreaâs No.1 beauty company and a blue-chip corporation. Amorepa...
Amorepacific is Koreaâs No.1 beauty company a...
CUTERA, Inc. was founded in 1998 and is a global provider of Face + Body laser, li...
CUTERA, Inc. was founded in 1998 and is a globa...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthro...
Eyenovia is a late-stage ophthalmic biopharmace...
Natureâs Sunshine Products (NASDAQ:NATR), a leading natural health and wellness ...
Natureâs Sunshine Products (NASDAQ:NATR), a l...
Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...
Headquartered in Waltham, Massachusetts, we dev...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Join the National Investor Network and get the latest information with your interests in mind.